775 related articles for article (PubMed ID: 22059152)
1. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.
Guo D; Reinitz F; Youssef M; Hong C; Nathanson D; Akhavan D; Kuga D; Amzajerdi AN; Soto H; Zhu S; Babic I; Tanaka K; Dang J; Iwanami A; Gini B; Dejesus J; Lisiero DD; Huang TT; Prins RM; Wen PY; Robins HI; Prados MD; Deangelis LM; Mellinghoff IK; Mehta MP; James CD; Chakravarti A; Cloughesy TF; Tontonoz P; Mischel PS
Cancer Discov; 2011 Oct; 1(5):442-56. PubMed ID: 22059152
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor LXR as a novel therapeutic antitumoral target in glioblastoma.
Moschetta A
Cancer Discov; 2011 Oct; 1(5):381-2. PubMed ID: 22586629
[TBL] [Abstract][Full Text] [Related]
3. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy.
Guo D; Prins RM; Dang J; Kuga D; Iwanami A; Soto H; Lin KY; Huang TT; Akhavan D; Hock MB; Zhu S; Kofman AA; Bensinger SJ; Yong WH; Vinters HV; Horvath S; Watson AD; Kuhn JG; Robins HI; Mehta MP; Wen PY; DeAngelis LM; Prados MD; Mellinghoff IK; Cloughesy TF; Mischel PS
Sci Signal; 2009 Dec; 2(101):ra82. PubMed ID: 20009104
[TBL] [Abstract][Full Text] [Related]
4. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism.
Zhou X; He W; Huang Z; Gotto AM; Hajjar DP; Han J
J Biol Chem; 2008 Jan; 283(4):2129-38. PubMed ID: 18029360
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.
Tanaka K; Babic I; Nathanson D; Akhavan D; Guo D; Gini B; Dang J; Zhu S; Yang H; De Jesus J; Amzajerdi AN; Zhang Y; Dibble CC; Dan H; Rinkenbaugh A; Yong WH; Vinters HV; Gera JF; Cavenee WK; Cloughesy TF; Manning BD; Baldwin AS; Mischel PS
Cancer Discov; 2011 Nov; 1(6):524-38. PubMed ID: 22145100
[TBL] [Abstract][Full Text] [Related]
6. TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis.
Hsieh J; Koseki M; Molusky MM; Yakushiji E; Ichi I; Westerterp M; Iqbal J; Chan RB; Abramowicz S; Tascau L; Takiguchi S; Yamashita S; Welch CL; Di Paolo G; Hussain MM; Lefkowitch JH; Rader DJ; Tall AR
Nature; 2016 Jul; 535(7611):303-7. PubMed ID: 27383786
[TBL] [Abstract][Full Text] [Related]
7. Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Acquaviva J; Jun HJ; Lessard J; Ruiz R; Zhu H; Donovan M; Woolfenden S; Boskovitz A; Raval A; Bronson RT; Pfannl R; Whittaker CA; Housman DE; Charest A
Cancer Res; 2011 Dec; 71(23):7198-206. PubMed ID: 21987724
[TBL] [Abstract][Full Text] [Related]
8. Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.
Ishibashi M; Masson D; Westerterp M; Wang N; Sayers S; Li R; Welch CL; Tall AR
J Lipid Res; 2010 Sep; 51(9):2655-63. PubMed ID: 20562239
[TBL] [Abstract][Full Text] [Related]
9. A novel role for c-Jun N-terminal kinase and phosphoinositide 3-kinase in the liver X receptor-mediated induction of macrophage gene expression.
Huwait EA; Greenow KR; Singh NN; Ramji DP
Cell Signal; 2011 Mar; 23(3):542-9. PubMed ID: 21070853
[TBL] [Abstract][Full Text] [Related]
10. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Schulte A; Liffers K; Kathagen A; Riethdorf S; Zapf S; Merlo A; Kolbe K; Westphal M; Lamszus K
Neuro Oncol; 2013 Oct; 15(10):1289-301. PubMed ID: 23877316
[TBL] [Abstract][Full Text] [Related]
12. Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.
Scotti E; Hong C; Yoshinaga Y; Tu Y; Hu Y; Zelcer N; Boyadjian R; de Jong PJ; Young SG; Fong LG; Tontonoz P
Mol Cell Biol; 2011 May; 31(9):1885-93. PubMed ID: 21343340
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro.
Padovani AM; Molina MF; Mann KK
Arterioscler Thromb Vasc Biol; 2010 Jun; 30(6):1228-36. PubMed ID: 20339114
[TBL] [Abstract][Full Text] [Related]
14. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.
Zelcer N; Hong C; Boyadjian R; Tontonoz P
Science; 2009 Jul; 325(5936):100-4. PubMed ID: 19520913
[TBL] [Abstract][Full Text] [Related]
15. Regulation of intestinal LDLR by the LXR-IDOL axis.
van Loon NM; van Wouw SAE; Ottenhoff R; Nelson JK; Kingma J; Scheij S; Moeton M; Zelcer N
Atherosclerosis; 2020 Dec; 315():1-9. PubMed ID: 33190106
[TBL] [Abstract][Full Text] [Related]
16. Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.
Haskins JW; Zhang S; Means RE; Kelleher JK; Cline GW; Canfrán-Duque A; Suárez Y; Stern DF
Sci Signal; 2015 Nov; 8(401):ra111. PubMed ID: 26535009
[TBL] [Abstract][Full Text] [Related]
17. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
[TBL] [Abstract][Full Text] [Related]
18. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.
Zhang L; Reue K; Fong LG; Young SG; Tontonoz P
Arterioscler Thromb Vasc Biol; 2012 Nov; 32(11):2541-6. PubMed ID: 22936343
[TBL] [Abstract][Full Text] [Related]
19. SREBP-2 positively regulates transcription of the cholesterol efflux gene, ABCA1, by generating oxysterol ligands for LXR.
Wong J; Quinn CM; Brown AJ
Biochem J; 2006 Dec; 400(3):485-91. PubMed ID: 16901265
[TBL] [Abstract][Full Text] [Related]
20. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
